{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:03Z","timestamp":1744258863692,"version":"3.40.4"},"reference-count":0,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Background: Intravenous immunoglobulin (IVIG) is the treatment of choice for humoral primary immunodeficiency diseases (PIDs). A third of the patients who receive intravenous immunoglobulin have adverse reactions, such as osmotic nephrosis.Objective: To assess the presence of kidney disease in adults with humoral PIDs, in treatment with intravenous immunoglobulin.Methods: A cross-sectional, descriptive, and observational study of patients who belong to the PID Clinic of the Specialties Hospital of the National Medical Center \u201cSiglo XXI\u201d, Mexico City, who receive treatment with intravenous immunoglobulin. A questionnaire with demographic information, 24h urine creatinine clearance, serum creatinine, urea, and BUN (Blood Urea Nitrogen) was applied.Results: 35 patients were surveyed; 65.7 % were women; the average age was 34 years; 51.4 % of the patients presented kidney damage. Those with &gt; 5 years of treatment with intravenous immunoglobulin presented chronic kidney disease (CKD) with more frequency (55.6 %) according to the KDOQI scale.Conclusions: Chronic kidney disease occurs in 51 % of adult patients with PID who have been treated with intravenous immunoglobulin for more than 5 years; which is why these patients require periodic evaluations of their kidney function, and the use of sugar-free immunoglobulin in order to reduce the risk.<\/jats:p>","DOI":"10.29262\/ram.v67i1.707","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T03:14:51Z","timestamp":1590376491000},"page":"25-33","source":"Crossref","is-referenced-by-count":0,"title":["Enfermedad renal cr\u00f3nica en adultos con inmunodeficiencias  primarias en tratamiento con inmunoglobulina intravenosa","Chronic kidney disease in adults with primary immunodeficiency diseases in treatment with intravenous immunoglobulin"],"prefix":"10.29262","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-1372","authenticated-orcid":false,"given":"Patricia Maria","family":"O'Farrill-Romanillos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8996-0985","authenticated-orcid":false,"given":"Ram\u00f3n Fabricio","family":"Luna-M\u00fajica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3860-6791","authenticated-orcid":false,"given":"Carlos Eduardo","family":"Contreras Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-2078","authenticated-orcid":false,"given":"Juan Carlos","family":"Anda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2020,1,9]]},"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/707\/2371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/707\/1246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/707\/1180","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/707\/2371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:08:27Z","timestamp":1744214907000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,29]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v67i1.707","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2020,1,9]]}}}